AcuCort AB (publ) (XSAT:ACUC)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.5680
-0.0030 (-0.53%)
At close: Sep 3, 2025
-0.53%
Market Cap139.73M
Revenue (ttm)8.00M
Net Income (ttm)-24.08M
Shares Out234.44M
EPS (ttm)-0.15
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume92,443
Average Volume402,435
Open0.5710
Previous Close0.5710
Day's Range0.5670 - 0.5770
52-Week Range0.5480 - 1.2000
Beta1.19
RSI43.60
Earnings DateAug 19, 2025

About AcuCort AB

AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. AcuCort AB (publ) was incorporated in 2006 and is based in Lund, Sweden. [Read more]

Industry Pharmaceutical Preparations
Founded 2006
Employees 4
Stock Exchange Spotlight Stock Market
Ticker Symbol ACUC
Full Company Profile

Financial Performance

In 2024, AcuCort AB's revenue was 7.72 million, an increase of 17.07% compared to the previous year's 6.59 million. Losses were -17.40 million, 27.1% more than in 2023.

Financial Statements

News

There is no news available yet.